New Delhi, Sep 25 (IANS) A new malaria monoclonal antibody is safe, well-tolerated, and can elicit protection in people with no prior exposure to the malaria-causing parasite, according to a study.
The phase 1 randomised controlled trial of the experimental monoclonal antibody MAM01, published in the journal The Lancet Infectious Diseases, showed that of the three malaria-naive adults given the highest study dose, none had parasites in their bloodstream up to 26 weeks later.
“Malaria-naive” refers to an individual who has never been exposed to the malaria parasite and therefore has no natural immunity to the disease.
“Although new vaccines are available, protective efficacy is not optimum. Monoclonal antibodies targeting the Plasmodium falciparum circumsporozoite protein have the potential to simplify prevention,” said corresponding author Prof Kirsten E Lyke, Center for Vaccine Development and Global Health, at the University of Maryland.
“MAM01 was well tolerated, met safety targets, and showed clinical proof-of-principle by eliciting protection in malaria-naive adults using the controlled human malaria infection model,” Lyke added.
According to data from the World Health Organization (WHO), malaria affected an estimated 263 million people worldwide and caused 597,000 deaths in 2023. Children under the age of five are particularly vulnerable, accounting for the highest proportion of malaria-related deaths.
For the study, the team randomly assigned 37 malaria-naïve adults aged 18 to 50 years to receive a single dose of MAM01 or a placebo from August 2023 to December 2024.
MAM01 administration was well tolerated, and no treatment-related serious adverse events occurred after one or two doses.
After infection, 6 of 6 participants in the control group and 18 of 22 participants in the MAM01 group had malaria parasites in their blood.
But “none of the three participants in the 40 mg/kg intravenous dose group developed parasitaemia. Pharmacokinetic analysis showed that serum MAM01 concentrations greater than 88 microgram/mL protected against malaria challenge,” the researchers said.
–IANS
rvt/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
